BR112013033342A2 - variantes de fc com funções atuadoras reduzidas - Google Patents
variantes de fc com funções atuadoras reduzidasInfo
- Publication number
- BR112013033342A2 BR112013033342A2 BR112013033342A BR112013033342A BR112013033342A2 BR 112013033342 A2 BR112013033342 A2 BR 112013033342A2 BR 112013033342 A BR112013033342 A BR 112013033342A BR 112013033342 A BR112013033342 A BR 112013033342A BR 112013033342 A2 BR112013033342 A2 BR 112013033342A2
- Authority
- BR
- Brazil
- Prior art keywords
- variants
- actuator functions
- reduced actuator
- reduced
- functions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11305811.9A EP2537864B1 (en) | 2011-06-24 | 2011-06-24 | Fc variants with reduced effector functions |
PCT/EP2012/062273 WO2012175751A2 (en) | 2011-06-24 | 2012-06-25 | Fc variants with reduced effector functions |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013033342A2 true BR112013033342A2 (pt) | 2017-01-31 |
Family
ID=45058478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013033342A BR112013033342A2 (pt) | 2011-06-24 | 2012-06-25 | variantes de fc com funções atuadoras reduzidas |
Country Status (8)
Country | Link |
---|---|
US (1) | US20140378663A1 (pt) |
EP (2) | EP2537864B1 (pt) |
JP (1) | JP6080844B2 (pt) |
CN (2) | CN103827142A (pt) |
BR (1) | BR112013033342A2 (pt) |
CA (1) | CA2840127C (pt) |
ES (1) | ES2755708T3 (pt) |
WO (1) | WO2012175751A2 (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI638833B (zh) | 2010-11-30 | 2018-10-21 | 中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
JP2014523900A (ja) | 2011-06-28 | 2014-09-18 | インヒブルクス リミティド ライアビリティ カンパニー | セルピン融合ポリペプチド及びその使用方法 |
KR102568808B1 (ko) | 2014-04-07 | 2023-08-18 | 추가이 세이야쿠 가부시키가이샤 | 면역활성화 항원 결합 분자 |
CA2943299A1 (en) | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Bispecific her2 antibodies |
JP6894702B2 (ja) | 2014-05-13 | 2021-06-30 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子 |
FR3024453B1 (fr) * | 2014-08-01 | 2018-06-29 | Lab Francais Du Fractionnement | Procede de production de variants ayant un fc presentant une sialylation amelioree |
DK3218406T3 (da) | 2014-11-10 | 2021-06-21 | Medimmune Ltd | Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf |
US20160129108A1 (en) | 2014-11-11 | 2016-05-12 | Medimmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and uses thereof |
FR3034420A1 (fr) * | 2015-03-31 | 2016-10-07 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-cd303 |
FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法 |
WO2017086419A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
JP2019528082A (ja) * | 2016-06-08 | 2019-10-10 | シャンハイ ジャオ トン ユニバーシティ スクール オブ メディシン | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
CN107759694B (zh) | 2016-08-19 | 2023-01-13 | 安源医药科技(上海)有限公司 | 双特异性抗体及其制备方法与用途 |
CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
WO2018032638A1 (zh) | 2016-08-19 | 2018-02-22 | 安源医药科技(上海)有限公司 | 用于构建融合蛋白的连接肽 |
MX2020001707A (es) * | 2017-08-15 | 2020-03-20 | Kindred Biosciences Inc | Variantes igg fc para uso veterinario. |
FR3081328B1 (fr) * | 2018-05-24 | 2021-01-01 | Lab Francais Du Fractionnement | Composition d'immunoglobulines humaines concentrees |
JP2022516505A (ja) | 2018-12-28 | 2022-02-28 | スパークス・セラピューティクス・インコーポレイテッド | 癌および他の疾患の治療のための、クローディン18.2に特異的な結合分子、その組成物および方法 |
CN111514291B (zh) * | 2020-05-05 | 2023-05-09 | 华中科技大学同济医学院附属协和医院 | 红斑狼疮IgG在制备抑制骨质损坏药物中的应用 |
US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR951412A (fr) | 1943-01-05 | 1949-10-25 | Thomson Houston Comp Francaise | Perfectionnements aux régulateurs de tension |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
MXPA01007170A (es) * | 1999-01-15 | 2002-07-30 | Genentech Inc | Variantes de polipeptidos con funcion efectora alterada. |
FR2879204B1 (fr) | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
WO2009009103A2 (en) * | 2007-07-10 | 2009-01-15 | Medimmune, Llc | CRYSTALS AND STRUCTURE OF HUMAN IgG Fc VARIANT |
EP2233500A1 (en) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
-
2011
- 2011-06-24 EP EP11305811.9A patent/EP2537864B1/en active Active
-
2012
- 2012-06-25 BR BR112013033342A patent/BR112013033342A2/pt not_active Application Discontinuation
- 2012-06-25 ES ES12735242T patent/ES2755708T3/es active Active
- 2012-06-25 CA CA2840127A patent/CA2840127C/en not_active Expired - Fee Related
- 2012-06-25 CN CN201280031137.2A patent/CN103827142A/zh active Pending
- 2012-06-25 WO PCT/EP2012/062273 patent/WO2012175751A2/en active Application Filing
- 2012-06-25 JP JP2014516393A patent/JP6080844B2/ja not_active Expired - Fee Related
- 2012-06-25 CN CN201710810571.5A patent/CN107474138A/zh active Pending
- 2012-06-25 US US14/128,828 patent/US20140378663A1/en not_active Abandoned
- 2012-06-25 EP EP12735242.5A patent/EP2723770B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2723770B1 (en) | 2019-07-31 |
CN103827142A (zh) | 2014-05-28 |
WO2012175751A2 (en) | 2012-12-27 |
ES2755708T3 (es) | 2020-04-23 |
EP2537864B1 (en) | 2019-08-07 |
EP2537864A1 (en) | 2012-12-26 |
CA2840127C (en) | 2020-02-18 |
CN107474138A (zh) | 2017-12-15 |
JP6080844B2 (ja) | 2017-02-15 |
US20140378663A1 (en) | 2014-12-25 |
CA2840127A1 (en) | 2012-12-27 |
JP2014519836A (ja) | 2014-08-21 |
WO2012175751A3 (en) | 2013-08-08 |
EP2723770A2 (en) | 2014-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013033342A2 (pt) | variantes de fc com funções atuadoras reduzidas | |
HRP20181690T1 (hr) | Varijante protutijela fc | |
DK3421595T3 (da) | Alfa-amylasevarianter | |
BR112014000673A2 (pt) | conjunto de válvula | |
CO6920260A2 (es) | Ambiente de aplicación múltiple | |
BR112014030459A2 (pt) | conjunto atuador de purgação | |
FR2976040B1 (fr) | Actionneur telescopique. | |
BR112013020613A2 (pt) | autoinjetor | |
BR112014001863A2 (pt) | sistemas de expressão baculovírus melhorados | |
BR112014007801A2 (pt) | conjunto de válvula | |
DK3384944T3 (da) | Autoinjektor | |
BR112013033506A2 (pt) | atuador linear | |
DE102012110637A8 (de) | Linear-Stellantrieb | |
DE112013001978T8 (de) | Betätigungsvorrichtung | |
FR2979475B1 (fr) | Actionneur lineaire | |
FR2977649B1 (fr) | Actionneur lineaire | |
BR112013029769A2 (pt) | levedura recombinante | |
FI20116167L (fi) | Järjestely | |
DE112012000803A5 (de) | Aktuatoreinrichtung | |
BR112014005603A2 (pt) | montagem de injetor | |
BR112013019094A2 (pt) | válvula de combustível anticapotamento | |
DK2691599T3 (da) | Armenhed | |
DE112011103981A5 (de) | Aktuator | |
FR2972076B1 (fr) | Actionneur magnetothermique. | |
BR112014015174A2 (pt) | conjunto de válvula |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |